Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
Vertex Pharmaceuticals to Acquire Crinetics for $10 Billion in Largest Deal Ever
00

Vertex Pharmaceuticals to Acquire Crinetics for $10 Billion in Largest Deal Ever

Jul 6, 2026

Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals on July 6, 2026, for approximately $10 billion in cash, marking the largest deal in Vertex's history. The $85-per-share price represents a 102% premium for Crinetics. The acquisition expands Vertex's portfolio into endocrinology, granting access to the FDA-approved acromegaly treatment Palsonify and the late-stage pipeline drug atumelnant, which together could generate over $5 billion in peak annual sales.

Vertex acquisition of Crinetics

  • ▪The acquisition of Crinetics Pharmaceuticals is the largest deal in the history of Vertex Pharmaceuticals, surpassing its $4.4 billion purchase of Alpine Immune Sciences in 2024
  • ▪Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for approximately $10 billion in cash, representing an equity value of about $85 per share
  • ▪The acquisition of Crinetics Pharmaceuticals by Vertex Pharmaceuticals is expected to close in the third quarter of 2026
  • ▪The purchase price of $85 per share represents a 102% premium over the closing price of Crinetics Pharmaceuticals stock on July 6, 2026

Pharmaceutical M&A activity surge

  • ▪Deep cash reserves, attractive biotech valuations, newly approved drugs, growing regulatory confidence, and patent losses are driving a wave of large pharmaceutical mergers and acquisitions in 2026
  • ▪The acquisition of Crinetics Pharmaceuticals by Vertex Pharmaceuticals represents one of the largest pharmaceutical deals of 2026

Palsonify acromegaly treatment launch

  • ▪Palsonify has shown early commercial momentum since its launch, according to Vertex Pharmaceuticals and Crinetics Pharmaceuticals
  • ▪The U.S. Food and Drug Administration approved Palsonify in September 2025 as a once-daily oral therapy to treat adults with acromegaly, a rare disorder caused by excess growth hormone

Atumelnant CAH pipeline development

  • ▪Vertex Pharmaceuticals and Crinetics Pharmaceuticals estimate that Palsonify and atumelnant could together generate more than $5 billion in peak annual sales
  • ▪Crinetics Pharmaceuticals is developing an experimental drug called atumelnant, which is in late-stage development for congenital adrenal hyperplasia

Vertex portfolio diversification strategy

  • ▪Vertex Pharmaceuticals, a dominant player in cystic fibrosis drugs, is seeking diversification through key growth areas including Casgevy and Journavx
  • ▪Vertex Pharmaceuticals is acquiring Crinetics Pharmaceuticals to expand its portfolio into endocrinology and treatments for rare hormonal diseases
  • ▪Vertex Pharmaceuticals expects the Crinetics Pharmaceuticals acquisition to add immediately to revenue growth and become accretive to adjusted operating income in 2029

3 sources

Bloomberg
Vertex to Acquire Crinetics for $10 Billion to Expand Endocrinology Portfolio
View source article
Reuters
Vertex to buy Crinetics for $10 billion to expand rare-disease business | Reuters
View source article
Aol
Vertex to buy Crinetics for $10 billion to expand rare-disease business - AOL
View source article
Share your thoughts

Will this acquisition prove successful for Vertex shareholders?

Story comments

Loading comments…

Share your thoughts

Will this acquisition prove successful for Vertex shareholders?

Topics

Drug Policy, Pricing & ApprovalPharma